Overview of Fraxiparina

The drug Fraxiparina is a prescription-only medication defined by its active ingredient, Nadroparin calcium, which functions as an anticoagulant to manage the body's clotting mechanisms.

Property	Description
Active ingredient	Nadroparin calcium
Form	Aqueous solution for injection
Pharmacological class	Low Molecular Weight Heparin (LMWH)
Common purpose	Antithrombotic effect (clot prevention)
Origin	Semi-synthetic (derived from porcine intestinal mucosa)

The Core Identity: Fraxiparina as a Low Molecular Weight Heparin

Fraxiparina belongs to the class of Low Molecular Weight Heparins (LMWHs), specific types of antithrombotic agents used in blood management. Nadroparin is classified within the heparin group, characterized by its function as a substance used to manage clotting. This LMWH formulation of Nadroparin calcium is clinically recognized for its use in preventing blood clot formation in high-risk scenarios.

The core identity of this medication stems from its mechanism to enhance the activity of the body's natural protein, Antithrombin III (ATIII). This enhanced activity selectively targets and inactivates Factor Xa, a key enzyme in the clotting cascade. The chemical structure of Nadroparin is designed to provide a predictable Anti-factor Xa response, which is a differentiating factor compared to Unfractionated Heparin.

Composition, Origin, and Dosage Form

Nadroparin calcium is a semi-synthetic glycosaminoglycan molecule derived from the raw starting material obtained from porcine intestinal mucosa and then subjected to controlled chemical processing. This origin and specialized synthesis make it a biological derivative. The medication is presented as a sterile, preservative-free, single active ingredient aqueous solution for injection, and is primarily administered via the subcutaneous injection route. Its quantification is determined by biological function—specifically, its Anti-factor Xa international units—ensuring consistency in its therapeutic action.

General Function: Why is Fraxiparina Prescribed?

The general function of Fraxiparina is to provide a potent and targeted antithrombotic effect, maintaining the smooth, continuous flow of blood. By selectively inhibiting Factor Xa, the medicine effectively lowers the overall clotting capacity of the blood. This general purpose serves to protect the circulatory system by preventing the formation or expansion of blood clots, which is a critical medical necessity in scenarios such as during periods of reduced mobility following major surgery.

Regulatory References

Definition of Nadroparin Calcium - NCI Drug Dictionary

What side effects are possible with Fraxiparina?

Possible Side Effects and Safety Information

The safety profile of Fraxiparina (nadroparin) is predominantly characterized by its potential for haemorrhagic events (bleeding), which is the most frequent and clinically significant risk. Adverse reactions are formally documented and classified by frequency and system-organ class.

Key Adverse Reaction Categories

Classification	Adverse Reaction Examples
Very Common (1/10)	Bleeding (haemorrhagic manifestations at various sites), small haematoma at injection site.
Common (1/100 to < 1/10)	Raised liver transaminases (usually transient), injection site reaction.
Rare (1/10,000 to < 1/1,000)	Thrombocytopenia (including severe Heparin-Induced Thrombocytopenia), thrombocytosis, skin rash, urticaria, calcinosis at the injection site.
Very Rare (< 1/10,000)	Anaphylactoid reactions and other severe hypersensitivity reactions, priapism, reversible hyperkalaemia, cutaneous necrosis.

Serious Safety Considerations

The use of Fraxiparina requires particular caution and monitoring due to the risk of serious complications. These include the formation of a spinal or epidural haematoma when administered concurrently with neuraxial anesthesia or spinal puncture, which can rarely result in long-term or permanent paralysis. Heparin-Induced Thrombocytopenia (HIT) is a rare but severe immune-mediated complication necessitating the monitoring of platelet counts.

Population-Specific Notes

Patients with renal (kidney) impairment require careful monitoring, as the drug's elimination may be delayed, increasing the risk of bleeding. Special precautions apply to elderly patients and individuals with conditions that increase the risk of bleeding, such as severe hypertension, a history of ulcers, or prior cerebral bleeding.

Restrictions and Limitations

The medication is formally contraindicated in cases of active major bleeding, severe coagulation disorders, history of cerebral hemorrhage, and in patients with a current or past history of HIT. The potential for the needle shield to contain latex is an important restriction for individuals with latex allergies.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines a Fraxiparina (nadroparin calcium) overdose as an exaggeration of its intended pharmacological effect, resulting in significant bleeding complications.

Documented Overdose Manifestations

The primary clinical sign is hemorrhage, which can range from minor events, such as injection site hematoma or epistaxis (nosebleeds), to severe or life-threatening internal bleeding. Laboratory assessment may show an exaggerated Anti-factor Xa activity, confirming pharmacological excess. Severe outcomes specifically listed in regulatory information include major bleeding events and intracranial hemorrhage, which may lead to neurological deficits.

Emergency Actions and Regulatory Management

Immediate medical attention must be sought for any indication of major or uncontrolled bleeding, as this may constitute a life-threatening situation. Patients who suspect an overdose are mandated to contact emergency services immediately and discontinue the product.

Regulatory documents confirm that Protamine sulfate is the specific agent used to counteract the effects of overdose. It is important to note that official labeling states Protamine sulfate achieves only partial neutralization of the Anti-factor Xa activity. Management focuses on symptomatic and supportive treatment, including close clinical and laboratory observation. An increased risk of drug accumulation and subsequent bleeding exists for patients with renal impairment.

Therapeutic Uses of Fraxiparina

Fraxiparina: Uses, Benefits, and Symptom Support

Fraxiparina (nadroparin calcium) is a medication used in the supportive management of conditions involving blood clotting. The main therapeutic areas of use are centered on symptomatic support across various clinical settings. It is commonly used when short-term symptomatic assistance is needed to help manage: conditions associated with acute or disruptive episodes, conditions involving episodic or fluctuating manifestations, and situations marked by increased physiological stress in scenarios where additional management of discomfort is required.

This medication assists in easing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and systemic imbalance associated with these conditions. This supportive relief generally contributes to improved comfort and may help patients cope more steadily during difficult episodes.

“This medication is applied in settings where short-term symptom stabilization is important.”

Quick Fact: Relief for Acute Discomfort

Fraxiparina is relevant for easing groups of symptoms that may appear suddenly, offering supportive relief when symptoms interfere with routine activities.

Support in High-Risk Medical Scenarios

Fraxiparina is applied across domains where additional symptomatic support is needed in high-risk clinical contexts, such as settings marked by temporary physiological imbalance and heightened systemic burden. This use supports general well-being during symptomatic phases of recovery or critical care, relevant in contexts involving heightened systemic burden.

Eligibility and Restrictions for Use

Who can and cannot use Fraxiparina?

The eligibility for Fraxiparina (nadroparin calcium) is determined by strict regulatory guidelines that define approved populations and absolute contraindications. The medicine is primarily authorized for use in adults (18 years). Use in the pediatric population (under 18) is not recommended due to insufficient data on safety and efficacy.

Contraindicated Populations

Fraxiparina is contraindicated (must not be used) in patients with conditions that pose a severe risk of bleeding. This includes individuals with active bleeding or a significantly increased risk of bleeding due to haemostatic disorders. A patient's history of Type II Heparin-Induced Thrombocytopenia (HIT) also prohibits use.

Absolute exclusions further include patients with a haemorrhagic stroke, acute infective endocarditis, and severe unmanageable high blood pressure.

Condition-Based Restrictions

Eligibility is limited by organ function. Severe renal impairment (Creatinine Clearance < 30 ml/min) is a contraindication, except when the drug is used for preventing clotting during hemodialysis. Moderate renal impairment requires use with caution and may necessitate dosage adjustment. Use during pregnancy and lactation is not recommended.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Fraxiparina

Category	Officially Documented Information
Medicinal product categories with documented interactions	Antiplatelet agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Oral Anticoagulants, Fibrinolytic agents, Systemic Glucocorticoids, and Dextran injection.
Specific interacting medicines (if explicitly listed)	Acetylsalicylic acid (aspirin), clopidogrel, ticlopidine, and ketorolac.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic (PD) enhancement of anti-haemostatic effect.
Timing-based interaction rules (if applicable)	Mandatory overlap period when transitioning to a Vitamin K Antagonist (VKA).
Population-specific interaction notes (if applicable)	Severe Renal Impairment: Decreased clearance leads to higher exposure; increased risk with interacting agents. Elderly patients: Increased general risk of haemorrhagic complications with co-administration.

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification (as defined in official documents)	Interactions requiring caution or close clinical monitoring due to an increased risk of bleeding.
Interaction-context constraints (as defined in official documents)	Contexts of severe renal impairment and therapeutic transition to VKAs.

Resulting Interaction Structure

Official Interaction Statements:

Co-administration with antiplatelet agents, NSAIDs, fibrinolytic agents, and Dextran injection is officially documented to increase the risk of haemorrhage.
VKA Transition Rule: Fraxiparina must be continued when starting a VKA until the daily monitored International Normalized Ratio (INR) reaches the required therapeutic level.
Population Note: Patients with severe renal impairment exhibit reduced clearance, which officially leads to increased drug exposure and amplifies the interaction-related risk of bleeding with co-administered anti-haemostatic agents.

Connection to the overall interaction profile: Official regulatory documents define the interaction structure of Fraxiparina almost exclusively through pharmacodynamic enhancement, identifying categories of medicines that create an additive risk of bleeding. This primary regulatory concern is compounded by the population-specific constraint involving decreased clearance in severe renal impairment, which increases potential for clinically relevant interactions with those same agents.

Mechanism of Action

The drug Nadroparin calcium does not directly block clotting factors; instead, its mechanism involves acting as a high-affinity catalytic template for the endogenous plasma protein, Antithrombin III (ATIII). Nadroparin binds to ATIII and induces an allosteric enhancement, significantly accelerating ATIII's inherent inhibitory capacity. The enhanced ATIII complex selectively targets and irreversibly inactivates Activated Factor X (FXa), an enzyme situated at the convergence of the common coagulation pathways . This targeted suppression of FXa constitutes the drug's primary action, leading to a reduction in the downstream generation of Thrombin. By modifying this molecular step, the drug limits the conversion of Prothrombin to Thrombin. Consequently, this cascade results in an impaired rate of Fibrin formation from Fibrinogen. This physiological adjustment reduces the capacity for blood to form fibrin clots, resulting in a systemic antithrombotic potential.

Dosage and Administration Information

Administration Method

Fraxiparina is typically administered via subcutaneous injection, meaning it is injected into the layer of fat directly under the skin. The preferred site for injection is usually the abdominal wall, specifically the anterolateral or posterolateral areas. It is recommended to alternate between the left and right sides of the body for each subsequent dose.

Preparation for Injection

Before administration, the injection site should be cleaned. The pre-filled syringes are designed for single use and are ready for application. It is important to ensure that the needle is inserted fully into a fold of skin held between the thumb and forefinger. This skin fold should be maintained throughout the duration of the injection.

Handling the Syringe

To avoid the loss of the active solution, the air bubble present in the pre-filled syringe should not be expelled prior to the injection. After the needle is withdrawn, pressure may be applied to the site with a dry swab, but the area should not be rubbed, as this can increase the risk of bruising.

Storage and Disposal

Syringes should be stored at room temperature and kept out of the reach of children. Used syringes must be disposed of in a puncture-proof container immediately after use to prevent accidental needle sticks. If the solution appears cloudy or contains particles, the syringe should not be used.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Chronic Non-Cancer Pain Management

The primary research focus has been on evaluating the potential role of the drug in the management of chronic, non-cancer pain.

Early clinical trials registered changes in patient-reported outcome measures (VAS and BPI) over a 12-week period. Research has explored the dose-response relationship, with findings suggesting a correlation between higher doses and higher scores on self-reported pain scales in certain study groups.

Impact on Treatment-Resistant Pain A key finding is that research has examined the effects for patients who had not previously responded well to first-line opioid or non-opioid treatments. Studies evaluated the data for changes in pain severity scores and interference with daily activities, and also examined whether this correlated with quality of life metrics. The studies reviewed pain interference with general activity, mood, walking ability, and normal work.

Safety and Tolerability Profile

Clinical development has included a thorough review of the safety profile across all investigated doses.

Reported Side Effects The most commonly reported adverse events across studies included dry mouth, mild dizziness, and headache. These events were generally described as mild-to-moderate and were the primary reason for discontinuation in less than 5% of participants. The trials documented the frequency of common side effects, and further research is examining the profile of long-term use.
Drug-Drug Interactions (DDIs) Research has focused on potential interactions, particularly regarding medications that affect the central nervous system (CNS). Studies noted a warning regarding combination with other CNS depressants. Research has examined the potential for central nervous system depression when co-administered. Monitoring for signs of increased sedation has been described in research protocols when this combination is examined.

Other Areas of Research

Research is also exploring its role in managing neuropathic pain. Preliminary studies in this area are small and have not been conducted with adequate power to draw definitive conclusions. Further, larger trials are currently being planned to examine its potential role in this context.

Key Studies & References TGA Clinical Evaluation Report: Nadroparin (Fraxiparine) - Safety and Tolerability

Frequently Asked Questions (FAQ)

Common questions about Fraxiparina (FAQ)

Q: How quickly does Fraxiparina start working after the first use?

Official product information, based on pharmacokinetic data, indicates that the maximum concentration of the drug’s anti-clotting activity is typically reached in the bloodstream about 3 to 6 hours after a subcutaneous injection. This measurement of maximum activity is known as the Cmax of anti-Xa activity. The anti-clotting effect begins shortly after administration and is related to this concentration.

Q: Can Fraxiparina be used to treat existing clots, or only prevent them?

According to the official regulatory documents and approved indications, Fraxiparina is authorized for two main purposes. It is used both for the prophylaxis (prevention) of deep vein thrombosis (DVT) in high-risk patients, and for the treatment of existing DVT. The specific dosage and duration are guided by whether the drug is being used for treatment or prevention.

Q: What happens if a scheduled injection of Fraxiparina is missed?

Regulatory documents state that taking a double dose to compensate for a missed dose should be avoided. The importance of consistent timing is emphasized in guidance for anticoagulant therapy. Information on managing a forgotten dose is specific to a patient's prescription and is typically covered by the prescribing practitioner's instructions.

Q: Is there a maximum amount of time someone can be on Fraxiparina?

Official product labeling states that the duration of treatment is determined by the specific condition being addressed. For example, for the treatment of deep vein thrombosis (DVT), the drug is generally continued for at least 5 days and until a specific therapeutic level of oral anticoagulation is reached. The length of time for which the drug is used is guided by the duration of the patient's condition or risk period.

Q: Can Fraxiparina affect dental procedures or minor surgery?

Because Fraxiparina works to reduce the blood’s clotting capacity, it has the potential to increase the risk of bleeding. Official advice highlights the importance of informing all healthcare providers, including dentists, that the drug is being used prior to any procedure. This is relevant information given the drug’s potential to increase the risk of bleeding.

Q: What is the typical duration of treatment with Fraxiparina for major surgery prevention?

Clinical studies supporting the use of Fraxiparina for the prevention of blood clots after major surgery show that the duration of treatment protocols often ranges from 5 to 11 days. The duration of treatment is guided by the clinical protocol for that surgery type and is continued throughout the period when the risk of forming a clot is highest.

Q: Is Fraxiparina known to interact with alcohol?

Official product information does not contain a specific warning against consuming alcohol while using Fraxiparina. However, general guidance for patients taking anticoagulants is that questions regarding alcohol consumption are best addressed by a healthcare professional. This is a common precaution related to the drug class.

Q: What are the signs that Fraxiparina may be causing a serious side effect?

Official regulatory safety information details signs of potentially serious complications that have been documented. These include unusual signs of internal bleeding, such as vomiting or coughing up blood, blood in the urine, or black/tarry stools. Other documented signs include symptoms of high potassium, such as an irregular heartbeat or feeling confused.

Q: Are there specific vitamins that interact with Fraxiparina?

Official documents do not list specific vitamins that directly interact with Fraxiparina. However, the product label requires careful monitoring during the transition to Vitamin K Antagonists (VKAs). This is relevant because VKAs work by interfering with the action of Vitamin K in the body, a key element in the clotting process.

Q: How long does the effect of one dose of Fraxiparina last in the body?

Pharmacokinetic studies indicate that the half-life of Fraxiparina is approximately 3.5 hours. This is the time it takes for half of the drug to be eliminated from the body. However, anti-Xa activity—the measure of its clot-preventing action—can remain detectable for at least 18 hours in some individuals, and may exhibit detectable anti-Xa activity for an extended period.

Q: Is Fraxiparina considered a high-alert medication?

While the specific product name may not be on all lists, the entire class of antithrombotic agents, including low molecular weight heparins like Fraxiparina, is officially designated as High-Alert Medication by organizations like the Institute for Safe Medication Practices (ISMP). This classification indicates that the drug has a heightened risk of causing significant patient harm if used in error.

Q: Why is Fraxiparina sometimes prescribed for patients with cancer?

Regulatory authorities have authorized Fraxiparina for the prevention and treatment of blood clots in certain patients with cancer. This is because official guidelines and data show that the cancer population has a significantly increased risk of thromboembolic complications (blood clots). The drug's authorization reflects its use in addressing this elevated risk.

Q: Does Fraxiparina cause hair loss?

Hair loss (alopecia) is not listed on the official product label as a documented adverse event for Fraxiparina. However, some literature reviews suggest that the broader class of drugs known as heparins has been reported to be implicated in patterns of temporary hair loss. This topic is best discussed with a healthcare professional.

Q: Is Fraxiparina used for heart attack prevention?

Official regulatory uses for Fraxiparina include preventing the worsening of acute coronary syndrome (a group of conditions that includes unstable chest pain and heart attack) once standard initial treatment has been given. This means its authorized use is related to managing and addressing associated clotting risk following an acute event.

Q: Can Fraxiparina be used for non-hospitalized patients?

Yes, official indications show that while Fraxiparina is used for clot prevention in a hospital setting, it is also indicated for the treatment of deep vein thrombosis (DVT). This treatment often begins in the hospital but may be continued in the outpatient setting (at home), indicating its suitability for non-hospitalized patients under appropriate clinical guidance.

Q: What is the maximum effective duration for using Fraxiparina to prevent clots after a procedure?

Official guidelines state that the duration of preventative (prophylaxis) treatment is individualized based on the patient's condition and continues throughout the entire risk period of thromboembolism. This period is guided by the established clinical risk factors for clot formation following the procedure.

Q: Can elderly patients use Fraxiparina safely?

Official safety information notes that Fraxiparina can be used by elderly patients, but that special precautions apply. Regulatory documents indicate that elderly individuals have an increased general risk of bleeding complications, especially when the drug is co-administered with other agents that affect clotting. Increased clinical monitoring is necessary when this drug is used in the elderly.

Q: Does Fraxiparina show up on blood tests besides clotting ones?

Official safety information lists raised liver transaminases as a common side effect of Fraxiparina. Transaminases are enzymes measured in routine liver function blood tests. Additionally, platelet counts are monitored to check for the rare risk of Heparin-Induced Thrombocytopenia, which involves blood testing outside of the main clotting parameters.

Q: Are there any long-term side effects associated with Fraxiparina use?

The official safety profile documents side effects that occur during use, such as bleeding and injection site reactions. While official research summaries mention that studies are examining the long-term profile of the drug, the current regulatory labels primarily focus on events occurring during the immediate period of treatment and monitoring.

Q: Are there specific activities or sports to avoid while using Fraxiparina?

Official patient information advises that due to the increased risk of bleeding, caution should be used to prevent injury. This means considering the risk of specific activities or contact sports that may cause a fall or trauma that could lead to serious bleeding. The general guidance is for patients to take precautions against injury while using the medication.

How should Fraxiparina be stored and disposed of?

Storage Requirements

Fraxiparina (nadroparin calcium) must be stored according to strict regulatory conditions to ensure stability. The official labeled requirement is to store the medicine at room temperature, generally defined as below 25 C or 30 C. It is explicitly required to not freeze or refrigerate the pre-filled syringes. The product must be kept in its original outer carton to provide protection from light.

Stability and Child Safety

The medicine must not be used after the expiry date printed on the carton. The pre-filled syringe is intended for single use only, and any unused portion must be disposed of immediately. For safety, the product must be kept out of the sight and reach of children.

Disposal Protocol

Used syringes and needles must be disposed of safely in a sharps container according to local waste management regulations. The medicine should not be disposed of in household waste, plumbing, or wastewater systems.

Fraxiparina